Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
— Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA
Phase 2b study design, including novel primary endpoint of endoscopic passability
— Study initiation on track, with first participants expected to be dosed in the second half of 2026
Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
Agomab Announces Results of Annual General Meeting
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.
All items on the agenda were approved, including:
• Approval of the statutory financial statements for the financial year ended December 31, 2025.
• Discharge to the current and former members of the Board of Directors and the statutory auditor in respect of the performance of their respective duties during the financial year ending on December 31, 2025.
• Reappointment of Mr. Ohad Hammer as a member of the Board of Directors for a term of one year.
• Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors for a term of four years.
The voting result and all documents relating to the shareholders’ meeting are available on the Agomab investor relations website at https://ir.agomab.com/governance/shareholder-meetings.
Agomab to Participate in Upcoming Conferences
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinicalstage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:
– ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled LungRestricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
– H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
– 2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
– JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
– BIO International Convention. Monday, June 22 – Thursday, June 25, 2026 in San Diego, CA.
– 2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.
“Our goal is to improve the lives of patients with fibrotic diseases. We are aiming to build a leading company that combines transformative science with the commitment and passion of our experienced team, partners, and investors.”
Tim Knotnerus, Chief Executive Officer
